Clinical and laboratory findings in all patients evaluated for hematologic or neurologic abnormalities
. | Treated patients . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Definite responders . | Possible responders . | Nonresponders . | Unevaluable for response . | Untreated patients . | |||
| Clinical abnormality, no. | 37 | 33 | 25 | 33 | 127 | |||
| Hematologic, no. (%) | 7 (19) | 15 (45) | 21 (84) | 18 (55) | 98 (77) | |||
| Neurologic, no. (%) | 29 (78) | 18 (55) | 1 (4) | 14 (42) | 22 (17) | |||
| Both, no. (%) | 1 (38) | 0 | 3 (12) | 1 (3) | 7 (6) | |||
| Cobalamin therapy, no. | 37 | 33 | 25 | 33 | NA | |||
| Oral, no. (%) | 7 (19) | 7 (21) | 9 (36) | 12 (36) | NA | |||
| Intramuscular, no. (%) | 30 (81) | 26 (79) | 16 (64) | 21 (64) | NA | |||
| Lowest Cbl, no. | 37 | 33 | 25 | 33 | 127 | |||
| Less than 201 pg/mL, no. (%) | 6 (16) | 6 (18) | 5 (20) | 8 (24) | 8 (6) | |||
| 201-300 pg/mL, no. (%) | 11 (30) | 12 (36) | 9 (36) | 12 (36) | 45 (36) | |||
| More than 300 pg/mL, no. (%) | 20 (54) | 15 (44) | 11 (44) | 13 (39) | 74 (58) | |||
| More than 400 pg/mL, no. (%) | 15 (41) | 9 (26) | 7 (28) | 8 (24) | 52 (41) | |||
| Highest MMA, no. | 5 | 31 | 25 | 29 | 112 | |||
| Less than 251 nmol/L, no. (%)* | 8 (23) | 14 (45) | 3 (12) | 9 (31) | 98 (88) | |||
| 251-376 nmol/L, no. (%) | 14 (40) | 7 (23) | 7 (28) | 13 (45) | 13 (11)† | |||
| More than 376 nmol/L, no. (%) | 13 (37) | 10 (32) | 15 (60) | 7 (24) | 1 (1)‡ | |||
| Highest HCys, no. | 33 | 27 | 21 | 27 | 101 | |||
| Less than 12.2 μmol/L, no. (%) | 16 (49) | 16 (59) | 8 (38) | 11 (41) | 89 (88) | |||
| 12.2-13.6 μmol/L, no. (%) | 2 (6) | 4 (15) | 4 (19) | 2 (7) | 4 (4) | |||
| More than 13.6 μmol/L, no. (%) | 15 (45) | 7 (26) | 9 (43) | 14 (52) | 8 (8) | |||
. | Treated patients . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|
. | Definite responders . | Possible responders . | Nonresponders . | Unevaluable for response . | Untreated patients . | |||
| Clinical abnormality, no. | 37 | 33 | 25 | 33 | 127 | |||
| Hematologic, no. (%) | 7 (19) | 15 (45) | 21 (84) | 18 (55) | 98 (77) | |||
| Neurologic, no. (%) | 29 (78) | 18 (55) | 1 (4) | 14 (42) | 22 (17) | |||
| Both, no. (%) | 1 (38) | 0 | 3 (12) | 1 (3) | 7 (6) | |||
| Cobalamin therapy, no. | 37 | 33 | 25 | 33 | NA | |||
| Oral, no. (%) | 7 (19) | 7 (21) | 9 (36) | 12 (36) | NA | |||
| Intramuscular, no. (%) | 30 (81) | 26 (79) | 16 (64) | 21 (64) | NA | |||
| Lowest Cbl, no. | 37 | 33 | 25 | 33 | 127 | |||
| Less than 201 pg/mL, no. (%) | 6 (16) | 6 (18) | 5 (20) | 8 (24) | 8 (6) | |||
| 201-300 pg/mL, no. (%) | 11 (30) | 12 (36) | 9 (36) | 12 (36) | 45 (36) | |||
| More than 300 pg/mL, no. (%) | 20 (54) | 15 (44) | 11 (44) | 13 (39) | 74 (58) | |||
| More than 400 pg/mL, no. (%) | 15 (41) | 9 (26) | 7 (28) | 8 (24) | 52 (41) | |||
| Highest MMA, no. | 5 | 31 | 25 | 29 | 112 | |||
| Less than 251 nmol/L, no. (%)* | 8 (23) | 14 (45) | 3 (12) | 9 (31) | 98 (88) | |||
| 251-376 nmol/L, no. (%) | 14 (40) | 7 (23) | 7 (28) | 13 (45) | 13 (11)† | |||
| More than 376 nmol/L, no. (%) | 13 (37) | 10 (32) | 15 (60) | 7 (24) | 1 (1)‡ | |||
| Highest HCys, no. | 33 | 27 | 21 | 27 | 101 | |||
| Less than 12.2 μmol/L, no. (%) | 16 (49) | 16 (59) | 8 (38) | 11 (41) | 89 (88) | |||
| 12.2-13.6 μmol/L, no. (%) | 2 (6) | 4 (15) | 4 (19) | 2 (7) | 4 (4) | |||
| More than 13.6 μmol/L, no. (%) | 15 (45) | 7 (26) | 9 (43) | 14 (52) | 8 (8) | |||